All lobbying filings

Strategic Marketing Innovations

Strategic Marketing Innovations filed a Q3 report for Tonix Pharmaceuticals on October 18, 2026, reporting $40,000 in lobbying income.

Lobbying for Tonix Pharmaceuticals · Clinical-stage biopharmaceutical company

As filed: STRATEGIC MARKETING INNOVATIONS for TONIX PHARMACEUTICALS.

All filings by Strategic Marketing Innovations · Everything Tonix Pharmaceuticals has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 18, 2026

Income

$40,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Defense

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Health Issues

Patient access to non-opioid analgesic drug treatments. Biodefense countermeasures fundings.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.